Cellanyx Diagnostics is at the forefront of advancing cancer diagnostics through its innovative use of AI-driven biomarker analysis and machine vision technologies. The company specializes in developing first-in-class phenotypic tests that assess the behavior and characteristics of live single tumor cells. This approach aims to enhance risk stratification for various solid tumors, including prostate, breast, kidney, bladder, and lung cancers. By leveraging live cell dynamics, Cellanyx's proprietary tests provide clinicians with valuable insights that augment traditional pathology, ultimately improving the decision-making process regarding treatment plans.

The technology employed by Cellanyx is designed to deliver clinically-proven, patented solutions that are both scalable and portable. Their laboratory-developed tests (LDTs) have been evaluated in nearly 500 patient samples, demonstrating the potential to reduce unnecessary treatment costs associated with surgeries or radiation for low-to-intermediate grade tumors. This innovative approach not only increases confidence in shared decision-making among patients and clinicians but also aims to improve overall patient outcomes by providing actionable insights into tumor aggressiveness.

United States

Cellanyx Diagnostics

Company Details